Transforming growth factors type B (TGF-beta s) are proteins forming 25 kD disulfide-linked homodimers which act to control the proliferation of a variety of both normal and transformed cell types. In addition, TGF-beta s have been shown to stimulate wound healing, and to act as potent immunosuppressive agents. Recently, we identified a new form of TGF-beta, which we termed TGF-beta 3. Sequence determination of three overlapping cDNA clones revealed an extensive homology of TGF-beta 3 with TGF-beta 1 and beta 2. The purpose of this Phase I research proposal is to express TGF- beta 3 cDNA in mammalian cell lines. Conditioned media of cells expressing high levels of TGF-beta 3 will be tested for their ability to modulate the growth of cells in both monolayer and soft agar. In Phase II, we propose to carry out a detailed analysis of the structure, function and potential therapeutic uses of recombinant TGF-beta 3.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA049337-01
Application #
3492193
Study Section
(SSS)
Project Start
1989-04-01
Project End
1989-09-30
Budget Start
1989-04-01
Budget End
1989-09-30
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Osi Pharmaceuticals, Inc.
Department
Type
DUNS #
City
Uniondale
State
NY
Country
United States
Zip Code
11553
ten Dijke, P; Iwata, K K; Thorikay, M et al. (1990) Molecular characterization of transforming growth factor type beta 3. Ann N Y Acad Sci 593:26-42